{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T21:35:28Z","timestamp":1794951328660,"version":"4.9.1"},"reference-count":26,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000892","name":"Prostate Cancer Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000892","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1016\/j.eururo.2025.01.015","type":"journal-article","created":{"date-parts":[[2025,2,6]],"date-time":"2025-02-06T23:26:58Z","timestamp":1738884418000},"page":"643-650","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"title":["Long-term Outcomes and Prognostic Impact of Residual Cancer Burden After Intensified Neoadjuvant Therapy in High-risk Prostate Cancer"],"prefix":"10.1016","volume":"87","author":[{"given":"Praful","family":"Ravi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucia","family":"Kwak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andres M.","family":"Acosta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saahil","family":"Rastogi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wanling","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aya","family":"Abdelnaser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David J.","family":"Einstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew A.","family":"Wagner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rana R.","family":"McKay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam S.","family":"Kibel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary-Ellen","family":"Taplin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.eururo.2025.01.015_b0005","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.ctrv.2008.08.002","article-title":"A systematic review and meta-analysis of randomised trials of neo-adjuvant hormone therapy for localised and locally advanced prostate carcinoma","volume":"35","author":"Shelley","year":"2009","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.eururo.2025.01.015_b0010","doi-asserted-by":"crossref","first-page":"3705","DOI":"10.1200\/JCO.2013.53.4578","article-title":"Intense androgen-deprivation therapy with abiraterone acetate plus leuprolide acetate in patients with localized high-risk prostate cancer: results of a randomized phase II neoadjuvant study","volume":"32","author":"Taplin","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2025.01.015_b0015","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1158\/1078-0432.CCR-16-1357","article-title":"Neoadjuvant enzalutamide prior to prostatectomy","volume":"23","author":"Montgomery","year":"2017","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.eururo.2025.01.015_b0020","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1200\/JCO.18.01777","article-title":"Evaluation of intense androgen deprivation before prostatectomy: a randomized phase II trial of enzalutamide and leuprolide with or without abiraterone","volume":"37","author":"McKay","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2025.01.015_b0025","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1097\/JU.0000000000001702","article-title":"Results of a randomized phase II trial of intense androgen deprivation therapy prior to radical prostatectomy in men with high-risk localized prostate cancer","volume":"206","author":"McKay","year":"2021","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2025.01.015_b0030","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1097\/JU.0000000000001632","article-title":"Outcomes of post-neoadjuvant intense hormone therapy and surgery for high risk localized prostate cancer: results of a pooled analysis of contemporary clinical trials","volume":"205","author":"McKay","year":"2021","journal-title":"J Urol"},{"issue":"6 Suppl","key":"10.1016\/j.eururo.2025.01.015_b0035","volume":"38","author":"Taplin","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2025.01.015_b0040","doi-asserted-by":"crossref","first-page":"3097","DOI":"10.1200\/JCO.2017.73.9987","article-title":"Metastasis-free survival is a strong surrogate of overall survival in localized prostate cancer","volume":"35","author":"Xie","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2025.01.015_b0045","doi-asserted-by":"crossref","first-page":"3032","DOI":"10.1200\/JCO.19.03114","article-title":"Event-free survival, a prostate-specific antigen-based composite end point, is not a surrogate for overall survival in men with localized prostate cancer treated with radiation","volume":"38","author":"Xie","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2025.01.015_b0050","doi-asserted-by":"crossref","first-page":"5005","DOI":"10.1200\/JCO.23.00617","article-title":"Biochemical recurrence surrogacy for clinical outcomes after radiotherapy for adenocarcinoma of the prostate","volume":"41","author":"Roy","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2025.01.015_b0055","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1097\/JU.0000000000002803","article-title":"Neoadjuvant novel hormonal therapy followed by prostatectomy versus up-front prostatectomy for high-risk prostate cancer: a comparative analysis","volume":"208","author":"Ravi","year":"2022","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2025.01.015_b0060","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/S1470-2045(21)00589-1","article-title":"Residual cancer burden after neoadjuvant chemotherapy and long-term survival outcomes in breast cancer: a multicentre pooled analysis of 5161 patients","volume":"23","author":"Yau","year":"2022","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.eururo.2025.01.015_b0065","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1016\/j.eururo.2022.09.009","article-title":"ARNEO: a randomized phase II trial of neoadjuvant degarelix with or without apalutamide prior to radical prostatectomy for high-risk prostate cancer","volume":"83","author":"Devos","year":"2023","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2025.01.015_b0070","doi-asserted-by":"crossref","first-page":"4414","DOI":"10.1200\/JCO.2007.10.6823","article-title":"Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy","volume":"25","author":"Symmans","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2025.01.015_b0075","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1200\/JCO.2012.48.6431","article-title":"Targeted androgen pathway suppression in localized prostate cancer: a pilot study","volume":"32","author":"Mostaghel","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2025.01.015_b0080","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1002\/pros.24653","article-title":"Adjuvant and salvage radiotherapy after neoadjuvant therapy and radical prostatectomy for high-risk localized prostate cancer","volume":"84","author":"Ravi","year":"2024","journal-title":"Prostate"},{"key":"10.1016\/j.eururo.2025.01.015_b0085","doi-asserted-by":"crossref","first-page":"1629","DOI":"10.1002\/cncr.35170","volume":"130","author":"McKay","year":"2024","journal-title":"Cancer"},{"key":"10.1016\/j.eururo.2025.01.015_b0090","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/j.eururo.2021.03.031","article-title":"Impact of pathogenic germline DNA damage repair alterations on response to intense neoadjuvant androgen deprivation therapy in high-risk localized prostate cancer","volume":"80","author":"Berchuck","year":"2021","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2025.01.015_b0095","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/S0167-9473(98)00096-6","article-title":"An application of changepoint methods in studying the effect of age on survival in breast cancer","volume":"30","author":"Contal","year":"1999","journal-title":"Comput Stat Data Anal"},{"key":"10.1016\/j.eururo.2025.01.015_b0100","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1038\/s41391-017-0009-6","article-title":"Post prostatectomy outcomes of patients with high-risk prostate cancer treated with neoadjuvant androgen blockade","volume":"21","author":"McKay","year":"2018","journal-title":"Prostate Cancer Prostat Dis"},{"key":"10.1016\/j.eururo.2025.01.015_b0105","doi-asserted-by":"crossref","unstructured":"Ravi P, Xie W, Buyse M, et al. Refining risk stratification of high-risk and locoregional prostate cancer: a pooled analysis of randomized trials. Eur Urol. In press. https:\/\/doi.org\/10.1016\/j.eururo.2024.04.038.","DOI":"10.1016\/j.eururo.2024.04.038"},{"key":"10.1016\/j.eururo.2025.01.015_b0110","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/S0140-6736(13)62422-8","article-title":"Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis","volume":"384","author":"Cortazar","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.eururo.2025.01.015_b0115","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1111\/bju.15434","article-title":"Optimal pathological response after neoadjuvant chemotherapy for muscle-invasive bladder cancer: results from a global, multicentre collaboration","volume":"128","author":"Ravi","year":"2021","journal-title":"BJU Int"},{"key":"10.1016\/j.eururo.2025.01.015_b0120","doi-asserted-by":"crossref","first-page":"3042","DOI":"10.1200\/JCO.20.00315","article-title":"Cancer and Leukemia Group B 90203 (Alliance): radical prostatectomy with or without neoadjuvant chemohormonal therapy in localized, high-risk prostate cancer","volume":"38","author":"Eastham","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2025.01.015_b0125","doi-asserted-by":"crossref","first-page":"2147","DOI":"10.1056\/NEJMoa1612645","article-title":"Adjuvant capecitabine for breast cancer after preoperative chemotherapy","volume":"376","author":"Masuda","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2025.01.015_b0130","doi-asserted-by":"crossref","first-page":"4433","DOI":"10.1200\/JCO.23.00435","article-title":"Standardized definitions for efficacy end points in neoadjuvant breast cancer clinical trials: NeoSTEEP","volume":"41","author":"Litton","year":"2023","journal-title":"J Clin Oncol"}],"container-title":["European Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0302283825000272?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0302283825000272?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T20:31:19Z","timestamp":1762288279000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0302283825000272"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":26,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["S0302283825000272"],"URL":"https:\/\/doi.org\/10.1016\/j.eururo.2025.01.015","relation":{},"ISSN":["0302-2838"],"issn-type":[{"value":"0302-2838","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Long-term Outcomes and Prognostic Impact of Residual Cancer Burden After Intensified Neoadjuvant Therapy in High-risk Prostate Cancer","name":"articletitle","label":"Article Title"},{"value":"European Urology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eururo.2025.01.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 European Association of Urology. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}